Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Dopamine agonists (dopaminergics) . |
| Generic Name : | Apomorphine |
| Drug description : | Solution for injection in 2mL or 5mL ampoules. |
| Presentation : | Solution for injection, apomorphine hydrochloride 1.0% w/ v (10mg/mL). |
| Indications : | Treatment of disabling motor fluctuations in patients with Parkinson's disease which persist after treatment with levodopa and/or other dopamine agonists. |
| Adult Dosage : | For subcutaneous use by intermittent bolus injection. May also be administered as a continuous subcutaneous infusion by minipump. It is essential that the patient is established on domperidone, usually 20mg three times daily for at least two days prior to initiation of therapy. Refer to Summary of Product Characteristics. |
| Child Dosage : | Under 18 years, contraindicated. |
| Contra Indications : | Respiratory depression, dementia, hepatic insufficiency. hepatic insufficiency. Intermittent apomorphine treatment is not suitable for patients who have an 'on' response to levodopa which is marred by severe dyskinesia or dystonia. Known sensitivity to apomorphine or to any other ingredients of the product. Not recommended for use in women of child-bearing potential. Breastfeeding not recommended. |
| Special Precautions : | Renal, pulmonary or cardiovascular disease. Persons prone to nausea and vomiting. Elderly and/or debilitated patients. Pre-existing cardiac disease, patients taking vasoactive drugs such as antihypertensives, pre-existing postural hypotension. Neuropsychiatric disturbance may be exacerbated by APO-go in some patients; there is also evidence from clinical studies that APO-go may improve these symtoms. |
| Interactions : | Neuroleptics, antihypertensives, cardiac active drugs. |
| Adverse Reactions : | Nausea and vomiting. Postural hypotension. Local subcutaneous injection site reactions including local induration and nodules (usually asymptomatic). Dyskinesia, neuropsychiatric disturbances. Transient sedation. Rarely, Coomb's positive haemolytic anaemia in patients treated with apomorphine and levodopa. Eosinophilia. |
| Manufacturer : | Britannia |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org